CinRx Portfolio Company CinDome Pharma Presents Encouraging Data on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference
![](https://cinrx.com/wp-content/uploads/2023/05/cinrx-portfolio-company-cindome-pharma-presents-encouraging-data-on-deudomperidone-cin-102-at-2023-digestive-disease-week-conference-1.jpg)
CinDome Pharma, a CinRx portfolio company, presented a poster at the 2023 Digestive Disease Week (DDW) Conference.
CinRx’s CinDome Pharma to Present a Poster on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference
![](https://cinrx.com/wp-content/uploads/2023/05/cinrx-portfolio-company-cindome-pharma-presents-encouraging-data-on-deudomperidone-cin-102-at-2023-digestive-disease-week-conference-1.jpg)
CinRx’s CinDome Pharma to Present a Poster on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference.
CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis
![](https://cinrx.com/wp-content/uploads/2023/05/cinrx-portfolio-company-cindome-pharma-presents-encouraging-data-on-deudomperidone-cin-102-at-2023-digestive-disease-week-conference-1.jpg)
CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis.